These impressive data on prognosis in hypertension should not obscure the fact that the outcome in individual cases of essential hypertension is highly unpredictable. Some patients, most of them women, may go through a normal or nearly normal span of life. However, a majority will die prematurely, not from hypertension or hypertensive vascular disease as such, but from complicaFroni the Research Division of The Cleveland Clinic Foundation, and The Frank E. Bunts Educational Institute, Cleveland, Ohio. tions of hypertensive and coronary heart disease, cerebrovascular damage or some other arterial (not arteriolar) catastrophe. Potent antihypertensive drugs have been in use for 7 to 8 years but with such a variable course and a lack of association between the cause of death and the extent of arteriolar damage it is impossible to assess therapeutic gains ini such terms as prolongation of life or preven. tion of complications. To be convincing, such an evaluation must await a survey of very large numbers of patients over long periods of time.
The situation is quite different when we deal with the malignant (accelerated) phase of essential hypertension. The course of this hypertensive syndrome is well characterized, predictable and relatively brief, with survival of only 10 to 20 per cent of patients for 1 vearY.-0 Death is caused primarily by hypertensive arteriolar vascular damage. This is commonly expressed by malignant nephrosclerosis with rapidly progressive renal failure, by intracerebral hematoma, and not infrequently by uncontrollable cardiac failure. A survey of survival and causes of death among a group of patients suffering from this comidition who have been under intensive treatment with potent antihypertensive agents available during the past 7 years, should establish the beneficial effects of these agents in terms of prolongation of life. Further, these drugs act in various ways to effect their common denominator of decreased arterial pressure. Hence, such a survey might also delineate those aspects of the vascular disease complication of treatment probably distorts the survival data of the first year, since it accounts for one third of the first-year mortality. The influence of this unfortunate complication can be estimated by comparing mortality (24 of the 84 patients) among the total first-year group with mortality in 33 patients observed after January 1, 1954, when the use of hexamethoniium had been discontinued. Among these 33 only 6 (18 per cent) died during the first year, whereas 9 or 10 deaths would have been anticipated. Hence, avoidance of pneumonitis seems to yield a definite gail in prognosis. We have no indication of the mechanism or pathogenesis of this complication.
It is exemplified by the course of a 44-yearold man who came with advanced malignant hypertension, heart failure and azotemia (serum creatinine 5.6 mg.j100 ml.). With hexamethonium, lying diastolic pressures were maintained at about 110 mm. Hg, papilledema regressed, proteinuria decreased, and congestive failure was easily controlled. At the end of 3 months, he developed severe dyspnea, which decreased on lying down. This symptom was progressive, and during the course of 2 weeks he developed pulmonary consolidation and died of diffuse pneumonitis.
The most common (42 per cent) single cause of death was renal failure. This occurred in 22 ARTERIAL PRESSURE AND SURVIVAL The control of blood pressure during treatment was considered 'igood" if the supine diastolic average was persistently less than 110 mm. Hg. Some patients whose responses were good at first later became resistant to treatment, so that control was "poor" during a large part of the treatment period. For simplicity's sake, these latter are considered here to have shown poor responses throughout.
First, we could establish iio association between the occurrence of hexainethonium pneumnollitis, the doses of drug used and the estimate of blood pressure control; this complication occurred, however, in patients with severe disease who showed some azotemia.
Among the 9 patients with rapidly progressive renal failure there were only 2 whose blood pressure control was considered good while poor responses were observed in the other 7, who also showed no more than a modest blood pressure fall when standing. However, even this slight degree of blood pressure control may be significant, since none of those with rapidly progressive renal failure who came to autopsy showed the florid and diffuse necrotizing renal arteriolar lesions characteristic of untreated malignant hypertension. Rather, the lesions were discrete and attenuated, beiiig more productive than inflammatory in appearance.9
Among the 13 patients with slowly progressive renal failure as a primary cause of death, there were 7 whose control was considered good and 6 in whom it was listed as poor. Apparently, in this group, the adequacy of blood pressure control is a less significant deterniinant of course than in those with rapidly progressive renal disease. Rather, the signifieant factors in this condition seem to be the extent and severity of the disease at the time treatment started and in particular the initial severity of renal disease.
The next major cause of death was cerebral hemorrhage. Among 13 patients who died of this complication 10 showed poor control and 3 good control. Control of supine diastolic pressure at levels under 110 mm. Hg therefore significantly reduces the risk of this complication. There were 7 patients who died of miyocardial infarction, 2 
